LHALA Doctor
Clinic-focused low-irritation peel adding INCUBE, PLLA and H2sol to LHA
About This Treatment
LHALA Doctor is positioned as a clinic-focused upgrade to LHALA Peel, adding INCUBE 501, INCUBE 701 (PLLA), QPT and calcium to the LHA/alkaline ingredient/lipid base. It targets gentle exfoliation plus barrier support, inflammation control, firmness and possible synergy with lasers or LEDs.
Peer-reviewed clinical trials of the LHALA Doctor product itself were not identified. Existing LHA and PLLA literature is only indirect support and should not be presented as direct proof of LHALA Doctor outcomes.
Mechanism of Action
LHA gently refines keratin and sebum congestion, while H2sol/P-Sol-type alkaline ingredients and lipids are intended to support the stratum corneum environment and barrier. Public materials describe INCUBE 501 for inflammation/wound-healing support, INCUBE 701 (PLLA) for collagen stimulation and QPT for light-device synergy. The clinical contribution of topical/peel PLLA particles remains unproven and should be distinguished from injectable PLLA evidence.
Indications
Expected Results
Short-term assessment focuses on radiance, smoothness and reduced dryness; firmness, pores and fine lines should be followed over multiple sessions. Because product-specific trials are lacking, stronger regenerative claims versus LHALA Peel should be framed as expected benefits based on indirect LHA/PLLA evidence and manufacturer/clinic materials.
Clinical Evidence
Risks & Side Effects
Possible transient redness, dryness, stinging, itching, flaking, acne flare, contact dermatitis and rare PIH. Because it is a clinic-focused product containing PLLA/growth-factor-like components, review allergy history, inflammatory dermatoses, timing with laser/LED treatments and recent retinoid or peel use.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition